US-based biopharmaceutical company AMAG Pharmaceuticals intends to raise $250m in gross proceeds through an underwritten public offering of convertible senior notes.
Underwriters will also be granted a 30-day option to purchase notes for a principal amount up to an additional $37.5m in order to cover any over-allotments.
Due 1 June 2022, the notes will help raise funds required for the company to repay its borrowings under its credit facility.
German biopharmaceutical company Noxxon Pharma has raised €10m ($10.9m) in gross proceeds through a private placement of ODIRNANE bonds, which are convertible into new shares and / or exchangeable for existing shares.
The company has also issued BSA share warrants for up to €10m ($10.9m) in multiple tranches.
It has concurrently raised €1m ($1.09m) through the private placement of 64,512 shares if its common stock priced at €15.5 ($16.9) a share.
The proceeds are intended to be used for general corporate purposes, as well as the clinical development of its drug candidate NOX-A12, which targets advanced solid tumours.
Teewinot Life Sciences has completed a series B financing round led by Tuatara Capital to raise $12.3m.
The proceeds will be used for enhancing and accelerating research and development (R&D), expanding business and acquiring patents.
US-based Teewinot is engaged in the discovery, development and commercialisation of cannabinoid-based therapeutics.
EPI Health is based in the US, while Cipher Pharmaceuticals is based in Canada. The sale helps Cipher to focus on speciality pharmaceuticals.
The transaction involved a cash consideration of $13.6m.
Beijing Biostar Technologies intends to conduct a private placement of shares to raise ¥50m ($7.25m).
Betta Pharmaceuticals has agreed to subscribe to the placement and will, as a result, own 4.5% stake in the issuing company.
Based in China, Beijing Biostar Technologies provides anti-cancer drugs.